Navigation Links
Phase 2a Findings Demonstrate that CSL112, A Novel Apolipoprotein A-I Infusion Therapy, Has a Favorable Safety Profile, is Well Tolerated and Increases Cholesterol Efflux Capacity in Stable Atherothrombotic Patients
Date:11/20/2013

60;                                       

No treatment-emergent serious adverse events (AE) were reported during the active treatment period except for one case of atrial fibrillation which occurred in the placebo group.  Assessments of liver function and other key biochemical, hematologic and immunogenic measurements over time were similar across all CSL112 and placebo groups.

PK and PD analyses showed that CSL112 caused immediate and robust increases in apoA-I, the active component of high density lipoprotein (HDL). Blood levels of apoA-I rose in a dose-proportional fashion with elevations approaching three-fold baseline levels at the top dose.  The highly anti-atherosclerotic form of HDL known as PreBeta1 showed an even greater elevation, with increases up to 17-fold. CSL112 also enhanced key biomarkers of the early steps of reverse cholesterol transport with strong elevations in cholesterol efflux capacity observed across all CSL112 regimens.  Changes were maintained for up to 72 hours after infusion of CSL112 at the higher doses.

Potential antiplatelet effects of CSL112 were also evaluated in this population of patients who were receiving chronic dual antiplatelet therapy.  CSL112 did not significantly influence platelet aggregation in response to AA, ADP and collagen. Based on these data, it is anticipated that CSL112 will not affect hemostasis when administered with concomitant antiplatelet therapies.

"Patients who experience an ACS event have a great unmet need to reduce the risk of suffering another heart attack, stroke or other cardiovascular event, particularly within the first 30 days," said Chuck Shear, CSL Cardiovascular Therapeutic Area Head. "The results of this third clinical stu
'/>"/>

SOURCE CSL Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
2. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
6. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
7. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
8. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
9. KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
10. Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma
11. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... GAITHERSBURG, Md. , May 28, 2015  GenVec, ... president and CEO, Douglas J. Swirsky , will ... Healthcare Conference at 11 a.m. EDT on Thursday, June ... webcast of Mr. Swirsky,s presentation will be available at ... also be available on GenVec,s website.  To access, visit ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce that ... with PTI Inspection Systems. Whitehouse Labs and PTI will ... method development and validation programs using the most ... includes a more formal program that facilitates cross training ... enables a more effective team approach, especially as it ...
(Date:5/28/2015)... Georgia (PRWEB) May 28, 2015 ... National Laboratory (Oak Ridge, TN) recently signed ... of 3D printing plastic resins using nanocellulose, a ... constraint of 3D printing is the limited number ... provide inadequate mechanical strength to printed parts for ...
Breaking Biology Technology:GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an ... to be launched by,the Company into the China market. ... I tests in July 2006, which consists of tests,for ... tested in,Phases II & III. Aida is currently undergoing ...
... and DETROIT, Oct. 22 The Michigan Life,Science ... rapidly,stimulate new business for Michigan companies. (Photo: ... BioPharma Company, LLC and the Michigan Virtual,Medical Device ... exhibit during,the MichBio Expo convention in Lansing, Michigan. ...
... Highlight and ... of Advanced Practices by Leading, Interventionalists, Broadcast from Around the World. - Hear About ... Stent, Results. - See How Many of the Major Fixed Imaging and Stent Manufacturers ... are Embracing IVUS., ...
Cached Biology Technology:Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 2Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 3Virtual Life Science Companies Launch and Tour 2Virtual Life Science Companies Launch and Tour 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... contains stem cells with a surprising capacity for repair, ... journal Cell, published by Cell Press. The novel insight ... have clinical implications for the treatment of brain damage, ... mice whose brains were severely damaged by loss of ...
... they have been exposed to biological or chemical weapons could ... who are helping to develop a tiny diagnostic device that ... of a tiny pump, researchers affiliated with MIT's Institute for ... existing miniature "lab on a chip" fully portable, so the ...
... heat-loving archaeon capable of fixing nitrogen at a surprisingly ... Earth’s earliest lineages of organisms capable of nitrogen fixation, ... and animals rely on to fix nitrogen. , ... of Science supports the notion that the gene needed ...
Cached Biology News:Neural stem cells lend the brain a surprising capacity for self-repair 2MIT designs portable 'lab on a chip' 2MIT designs portable 'lab on a chip' 3Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
... ZMD.440. Immunogen: Synthetic peptide derived from ... (platelet derived growth factor D iris-expressed growth ... differs from mouse and rat by one ... the ~50 kDa human mouse and rat ...
...
...
...
Biology Products: